Cartesian Therapeutics (RNAC) Enters $130M Private Placement
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazilās Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Britain will not join Canada-led defence bank initiativeĀ
- CAE agrees to sell Flightscape unit to SITA for $500 million
Oppenheimer Downgrades Cartesian Therapeutics (RNAC) to Perform
July 2, 2024 11:27 AM EDTOppenheimer analyst Matthew Biegler downgraded Cartesian Therapeutics (NASDAQ: RNAC) from Outperform to Perform.
The analyst comments "Weve been bullish on this nameand while the topline results looked excellent at first glance, we just cant get over the ITT versus per protocol... More



